Efficacy and Safety of Ab-Interno Canaloplasty in Post-Keratoplasty Patients: 3-Year Results

被引:0
|
作者
Redden, Liam D. [1 ]
Riaz, Kamran M. [1 ]
Murphy, David A. [1 ]
Ding, Kai [1 ]
Khaimi, Mahmoud A. [1 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Dean McGee Eye Inst, Oklahoma City, OK 73104 USA
来源
CLINICAL OPHTHALMOLOGY | 2024年 / 18卷
关键词
ab-interno canaloplasty; keratoplasty; intraocular pressure; glaucoma; AUTOMATED ENDOTHELIAL KERATOPLASTY; RISK-FACTORS; PENETRATING KERATOPLASTY; OCULAR HYPERTENSION; GRAFT-SURVIVAL; GLAUCOMA; MANAGEMENT; TRABECULOTOMY; PHACOEMULSIFICATION; VISCODILATION;
D O I
10.2147/OPTH.S487384
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the effectiveness and safety of ab-interno canaloplasty (ABiC) for managing intraocular pressure (IOP) in patients following keratoplasty over a three-year period. Methods: This retrospective analysis focused on post-keratoplasty patients treated with ABiC with the iTrack microcatheter (Nova Eye Medical, Fremont, CA, USA) at a single institution. The study assessed the procedure's impact on IOP control, graft survival, and reliance on topical hypotensive medications, with additional observation for any postoperative complications. Surgical success criteria included the percentage of eyes with IOP <= 15 mmHg, IOP <= 18 mmHg, >= 20% IOP reduction, medication-free eyes, and eyes with concurrent IOP and medication reductions. Results: ABiC was performed successfully in a cohort of 16 post-keratoplasty (7 penetrating keratoplasty and 9 endothelial keratoplasty (EK)) eyes. Preoperative mean IOP of 25.8 +/- 7.2 mmHg was significantly reduced to 13.4 +/- 2.9 mmHg (p<0.001) at 1 year postoperatively and maintained at 13.1 +/- 3.9 mmHg (p=0.009) at 3 years postoperatively. The mean number of glaucoma medications was 3.5 +/- 1.7 at baseline, 2.8 +/- 1.3 at 1 year (p=0.107), and 2.5 +/- 1.2 at 3 years postoperatively (p=0.088). Eight eyes (66.7%) maintained IOP <= 15 mmHg, and 10 eyes (83.3%) maintained >= 20% IOP reduction at 3 years. The mean IOP and medication reductions from baseline at 3 years were -49.2% and -28.6%, respectively. Graft clarity was preserved in all patients except for one case of late graft failure that necessitated a repeat EK procedure. Post-ABiC complications included transient hyphema in two patients, neither of which led to long-term adverse outcomes. Conclusion: ABiC appears to be an effective and safe surgical intervention for sustained IOP reduction in post-keratoplasty patients. Graft survival trends are encouraging, and there was a low incidence of complications over a three-year follow-up period.
引用
收藏
页码:3567 / 3577
页数:11
相关论文
共 50 条
  • [31] Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
    Tanihara, Hidenobu
    Kakuda, Takahiko
    Sano, Tetsuro
    Kanno, Takashi
    Imada, Ryosuke
    Shingaki, Wataru
    Gunji, Ryoji
    ADVANCES IN THERAPY, 2019, 36 (02) : 333 - 343
  • [32] Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study
    Hidenobu Tanihara
    Takahiko Kakuda
    Tetsuro Sano
    Takashi Kanno
    Ryosuke Imada
    Wataru Shingaki
    Ryoji Gunji
    Advances in Therapy, 2019, 36 : 333 - 343
  • [33] Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at &lt;4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial
    Muntau, Ania C.
    Burlina, Alberto
    Eyskens, Francois
    Freisinger, Peter
    Leuzzi, Vincenzo
    Sivri, Hatice Serap
    Gramer, Gwendolyn
    Pazdirkova, Renata
    Cleary, Maureen
    Lotz-Havla, Amelia S.
    Lane, Paul
    Alvarez, Ignacio
    Rutsch, Frank
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [34] Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study
    Huh, Lyang
    Lee, Bong Ju
    PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, 2019, 29 (04) : 399 - 406
  • [35] Post-operative weight loss affects 3-year survival in patients with gastric adenocarcinoma after gastrectomy and hyperthermic intraperitoneal chemotherapy
    Funk-Debleds, Pamela
    Rossi, Julien
    Bernard, Lorraine
    Galan, Alexandre
    Kepenekian, Vahan
    Glehen, Olivier
    Chambrier, Cecile
    EJSO, 2023, 49 (09):
  • [36] Are hospitalized patients with inflammatory bowel disease at increased risk of invasive bacterial infections? Results from POLIBD 3-year cohort study
    Gruszecka, Jolanta
    Filip, Rafal
    GUT PATHOGENS, 2021, 13 (01)
  • [37] Are hospitalized patients with inflammatory bowel disease at increased risk of invasive bacterial infections? Results from POLIBD 3-year cohort study
    Jolanta Gruszecka
    Rafał Filip
    Gut Pathogens, 13
  • [38] Safety and effectiveness of empagliflozin in clinical practice as monotherapy or with other glucose-lowering drugs in Japanese patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance study
    Kaku, Kohei
    Nakayama, Yayoi
    Yabuuchi, Junko
    Naito, Yusuke
    Kanasaki, Keizo
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 819 - 832
  • [39] Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience
    Blanc, Julie
    Deschasse, Clemence
    Kodjikian, Laurent
    Dot, Corinne
    Bron, Alain-Marie
    Creuzot-Garcher, Catherine
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 256 (08) : 1441 - 1448
  • [40] Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
    Mayo, Marlyn J.
    Vierling, John M.
    Bowlus, Christopher L.
    Levy, Cynthia
    Hirschfield, Gideon M.
    Neff, Guy W.
    Galambos, Michael R.
    Gordon, Stuart C.
    Borg, Brian B.
    Harrison, Stephen A.
    Thuluvath, Paul J.
    Goel, Aparna
    Shiffman, Mitchell L.
    Swain, Mark G.
    Jones, David E. J.
    Trivedi, Palak
    Kremer, Andreas E.
    Aspinall, Richard J.
    Sheridan, David A.
    Doerffel, Yvonne
    Yang, Ke
    Choi, Yun-Jung
    McWherter, Charles A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 186 - 200